Following its benchmark discovery, nitric oxide (NO) is now known to play important functional roles in a variety of physiological systems. Within the vasculature, NO induces vasodilation, inhibits platelet aggregation, prevents neutrophil/platelet adhesion to endothelial cells, inhibits smooth muscle cell proliferation and migration, regulates programmed cell death (apoptosis) and maintains endothelial cell barrier function. NO generated by neurons acts as a neurotransmitter, whereas NO generated by macrophages in response to invading microbes acts as an antimicrobial agent. Because neurons, blood vessels and cells of the immune system are integral parts of the reproductive organs, and in view of the important functional role that NO plays in those systems, it is likely that NO is an important regulator of the biology and physiology of the reproductive system. Indeed, in the past 10 years, NO has established itself as a polyvalent molecule which plays a decisive role in regulating multiple functions within the female as well as the male reproductive system. This review provides an overview of the role of NO in various reproductive organs under physiological and pathological conditions. Palmer et al. (1987) and Ignarro et al. (1987) provided evidence that EDRF is nitric oxide (NO). One year later, Palmer et al. (1988) reported that NO is synthesized from L-arginine, and Marletta et al. (1988) reported that macrophages generate nitrite and nitrate from L-arginine. Garthwaite et al. (1988) also provided evidence for the presence and synthesis of NO in brain. During the period from 1988 to 1992, research on the biology and functions of NO escalated, and then in 1992, 'NO was named 'Molecule of the Year' by D.E.Koshland, Jr., Editor for Science.
A third isoform is an inducible calcium-independent form (iNOS or NOS2) that is expressed only in response to inflammatory cytokines and lipopolysaccharides (LPS; reviewed in Nussler and Billiar, 1993; Morris and Billiar, 1994) . The three isoforms of NOS are products of separate genes that share 50-60% amino acid homology (Nathan and Xie, 1994) . However, all three isoforms are presumed to function as a homodimer during activation, sharing a carboxy-terminal reductase domain homologous to the cytochrome P-450 reductase and an amino-terminal oxygenase domain containing a haem prosthetic group, which are linked roughly in the middle of the protein by a calmodulin-binding domain (Dinerman et al., 1993; Abu-Soud et al., 1994 Forstermann et al., 1994; Sessa, 1994; Su et al., 1995) . The reductase domain of each NOS isoform contains tetrahydrobiopterin (THB) which is required for the efficient generation of NO and is necessary to maintain a stable conformation for electron transport, possibly by promoting homodimerization (Cho et al., 1995; Klatt et al., 1995; Tzeng et al., 1995; Ghosh et al., 1996) . Moreover, the haem prosthetic group appears to be necessary for THB binding and enzyme dimerization (Klatt et al., 1996) .
Increases in intracellular calcium triggers a cascade of events leading to cNOS activation and NO synthesis. Intracellular calcium binds to calmodulin to form a calcium-calmodulin complex and regulates the binding of calmodulin to the 'latch domain', which permits electron transfer from NADPH via flavin groups within the reductase domain to a haem-containing active site, thereby facilitating the conversion of O 2 and L-arginine to NO and L-citrulline (Abu-Soud et al., 1994, 1995a,b; Su et al., 1995; Siddhanta et al., 1996.) . In contrast to cNOS, iNOS contains calmodulin tightly bound to each subunit of the enzyme, and therefore activation of iNOS does not require an increase in intracellular calcium and results in the permanent activation of the enzyme (Cho et al., 1992) . Indeed, calcium chelators have been shown to reduce cNOS activity significantly; however, with regard to iNOS activity, the role of calcium remains unclear, as Gellar et al. (1993) showed that calcium chelators significantly reduced iNOS activity, whereas Charles et al. (1993) reported that iNOS activity was not influenced by calcium chelators.
Apart from calcium, several other factors can regulate NOS activity. Pre-as well as post-translational and transcriptional mechanisms have been shown to regulate the expression of all forms of NOS and are beyond the scope of this review Kelly et al., 1996) . Although iNOS is cytosolic, cNOS possesses a site for myristylation, enabling it to link to the cell membrane . Phosphorylation of cNOS by protein kinase C or A is associated with the detachment of the enzyme from the cell membrane and loss of activity Michel et al., 1993) . Potential phosphorylation sites also exist in iNOS (Geller et al., 1993) ; however, no functional significance has been demonstrated.
L-Arginine is the only physiological nitrogen donor for NOS-catalysed reactions; hence availability of this essential substrate could determine rates of NO generation. Arginine synthesis as well as its transport into the cells can also influence NO synthesis. Arginine is synthesized from citrulline by the actions of arginosuccinate synthetase and arginosuccinate lyase (Morris, 1992) and catabolized by arginase (Albina et al., 1988) . It has been shown that endogenous arginine synthesis is coupled to NO synthesis and that induction of arginosuccinate synthetase is not secondary to increased NOS activity Nussler et al., 1994) . Moreover, low concentrations of arginine caused by the release of arginase in wounds are responsible for the reduced NO synthesis (Albina et al., 1988) . Apart from synthesis, transport of arginine into the cells can also regulate NOS activity. In this regard, it has been shown that hepatic L-arginine transport, which is normally low, is enhanced during sepsis and after treatment with LPS (Sax et al., 1988; Inoue et al., 1993) . Competitive inhibition of arginine uptake by L-lysine, L-ornithine (naturally occurring amino acids) and nitro-L-arginine methyl ester (L-NAME) or N g -monomethyl-L-arginine (L-NMMA, arginine analogues) results in decreased NO synthesis (Bogle et al., 1992; Inoue et al., 1993) . NOS activity may not always be co-regulated by L-arginine transport, as dexamethasone inhibits induction of macrophage iNOS but not arginine transport (Baydoun et al., 1993) . Overall, arginine synthesis and transport represents a potential target for experimental and therapeutic manipulation of cellular NO synthesis.
Because NOS activity is dependent on substrate availability and the co-factors NADPH, flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), THB, the availability of these factors determines the cellular rates of NO synthesis. Maximal activation of NOS requires NADPH, FAD, FMN, THB and reduced thiol Davies et al., 1995; Kelly et al., 1996) . This implies that the activities of metabolic pathways that generate or compete for these cofactors under physiological and pathological conditions could play an important role in determining rates of cellular NO production. NADPH synthesis has been shown to be co-induced with iNOS. Moreover, the activity of the NADPH-generating pentose phosphate pathway, and of the rate-limiting enzyme glucose 6-phosphate dehydrogenase, in particular, has been shown to correlate with NO production (Corraliza et al., 1993; Morris and Billiar, 1994) . Additionally, glucose, which stimulates NADPH synthesis via the pentose phosphate pathway, stimulates the conversion of L-arginine to L-citrulline, possibly via NOS (Blachier et al., 1991) . Suppression of endogenous glutathione in endothelial cells has been shown to result in a decrease in NO synthesis, and these effects are likely due to a non-specific reduction in cellular redox capacity (Murphy et al., 1991) . THB, a reduced cofactor which is synthesized from guanosine triphosphate (GTP) by the action of GTP-cyclohydrolase I (GTPcyclohydrolase; the first and rate-limiting enzyme in denovo synthesis of THB), plays a crucial role in maintaining NOS activity (Gross and Levi, 1992; Kaufman, 1993) . Stoichiometric evidence suggests that each molecule of THB allows for the generation of 18 molecules of NO without any recycling of THB (Giovanelli et al., 1991) , suggesting that THB has a catalytic or structural role for NOS. Indeed, THB is essential in forming the active dimeric enzyme for iNOS monomers and maintaining iNOS in an active configuration (Baek et al., 1993) . In pulmonary artery smooth muscle cells stimulated with cytokines or LPS, increases in guanosine triphosphate cyclohydrolase (GTP-CH) concentrations are co-induced with iNOS (Nakayama et al., 1994) . Similar co-induction was first observed in fibroblasts in response to interferon (IFN)-γ (Werner-Felmayer et al., 1990) . Increases in GTP-CH alone, and not NOS expression, has been shown to account for tumour necrosis factor (TNF), IFN-γ or LPS-induced increases in eNOS activity (Werner-Felmayer et al., 1993) .
NOS activity can also be inhibited by blocking flavoproteins and inhibiting haem (Nathan, 1992) . Moreover, NO itself can regulate its own activity. This is clearly evident from the findings that NO synthesis is not linear after 20 min and suggests the possibility of feed-back inhibition (Assreuy et al., 1993) . NO donors have been shown to inhibit cNOS activity in a partially reversible manner, whereas NO scavengers prolong the linear kinetics of the enzyme (Rogers and Ignarro, 1992; Buga et al., 1993) . Because NO reacts with haem and non-haem iron, it has been postulated that NO inactivates the haem centre in the NOS enzyme (Assreuy et al., 1993) . In this regard, both cNOS and iNOS have been shown to form ferrous-nitrosyl complexes in their haem prosthetic groups (Abu-Soud et al., 1995a,b; Hurshman and Marletta, 1995) . Increased production of NO by cytokines has been shown to reduce haem availability and insertion into newly synthesized iNOS monomer (Albakri and Stuehr, 1996) . Regulation of NO synthesis by product inhibition may have important implications under physiological and pathological circumstances, as it may increase NO synthesis in the presence of substances that decrease NO and decrease NO synthesis in situations when NO accumulates.
Because of the close homology and sharing of enzymatic properties with cytochrome P-450, studies have linked the oxidative component of NOS to cytochrome P-450 (Bredt et al., 1991) . In this regard, NOS has been shown to generate hydrogen peroxide, superoxide as well as NO (Heinzel et al., 1992; Pou et al., 1992) . In L-arginine-depleted cells, superoxide generation is increased, whereas the presence of L-arginine reduces superoxide generation (Xia et al., 1996) . Superoxide (@O 2 -) generated at low concentrations of L-arginine reacts with NO, resulting in increased generation of peroxynitrite (ONOO -) and cell toxicity. Moreover, the generation of @O 2 -and ONOO -as well as cell toxicity was blocked by the specific NOS blocker N-nitro-L-arginine methyl ester (L-NAME; Xia et al., 1996) . Different methodology has been used to identify NO in physiological media or in different biological models. The various assays available for measurement of NO were recently reviewed by Archer (1993) .
NO transport and mechanism of biological action
Initially it was believed that NO reaches its intracellular targets by freely diffusing through the cell membranes. However, because of its ultra-short half-life (<30 s) and high reactivity with @O 2 -, haem and non-haem-iron, the concept of free diffusion of NO was hard to accept. Because NO reacts with thiol (-SH) groups of proteins, it can form stable, biologically active, S-nitrosyl compounds (Stamler et al., 1992) . Indeed, NO has been shown to circulate as an S-nitroso adduct of albumin and possess biological activities identical to those of NO in vitro and in vivo (Keaney et al., 1993) . Since iron-nitrosyl compounds are associated with thiol-containing ligands, formation of dinitrosyl iron cysteine has been suggested as a second pathway for NO transport (Mulsch et al., 1993) .
NO is now known to mediate multiple biological effects, although initially the effects of NO were thought to be solely mediated via activation of soluble guanylate cyclase and guanosine 3',5'-cyclic monophosphate (cGMP). Generation of cGMP is known to mediate relaxation, inhibit vascular smooth muscle cell growth and prevent platelet aggregation and adherence of neutrophils to endothelial cells (Murad, 1994) . However, recent studies suggest that NO can also induce its biological effects via non-cGMP-dependent pathways. Since NO is paramagnetic, it is capable of forming high-affinity-nitroso complexes with a variety of metal complexes (Lancaster et al., 1992) . NO binds to the haem-containing proteins, for example oxyhaemoglobin, and to iron-sulphur-containing proteins of the tricarboxylic acid cycle enzyme cis-aconitase. NO can also bind to the thiol (-SH) groups of glyceraldehyde-3-phosphate dehydrogenase (GADPH), and via this mechanism NO is thought to decrease glycolytic activity associated with myocardial stunning, reperfusion injury and neurotoxicity and to inhibit mitochondrial respiration (Moncada et al., 1991 ; reviewed by Kelly et al., 1996) . Other relevant mechanisms may include S-nitrosylation of thiols, formation of nitrotyrosines, NO binding to iron-sulphur clusters and NO binding to haem-containing proteins of the respiratory chain (McDonald and Moss, 1993; Mohr et al., 1996) . NO has been shown to inhibit GADPH activity by covalent linkage to NAD or NADH. NO can also act as a free radical scavenger and inactivate @O 2 -, thereby preventing cell toxicity (Cook and Tsao, 1993) . However, under appropriate conditions, reaction of NO with @O 2 -can also result in the generation of peroxynitrite (ONOO -), a potent oxidant (Beckman et al., 1990; Beckman and Crow, 1993) . Peroxynitrite decomposes to form the reactive hydroxyl radical HOONO. Moreover, peroxynitrite and its metabolite are capable of inducing cytotoxicity by inducing lipid peroxidation, nitrosation of several tyrosine molecules that regulate enzyme function and signal transduction and Na + channel inactivation. Together, these findings suggest that the actions of NO in a cell depend on its concentration, the cellular redox state, and the abundance of metals, protein thiols and low-molecular weight thiols (glutathione), as well as other nucleophil targets (Davies et al., 1995;  reviewed by Kelly et al., 1996) . NO as a regulator of physiology and biology of the male and female reproductive systems NO is now known to be produced by various cells in different organs, including smooth muscle cells, mesangial cells, neurons, platelets, hepatocytes, macrophages, fibroblasts and epithelial cells. NO regulates smooth muscle cell tone, platelet aggregation and adhesion, cell growth, apoptosis, neurotransmission and injury as well as infection-induced immune reactions. Because these processes are also associated with the biology, physiology and pathophysiology of various reproductive processes, it is highly likely that NO plays an important role in reproduction. Indeed, in the past decade NO has been recognized as a molecule that importantly regulates the biology and physiology of the reproductive system (Figure 1 ). 
NO in the female reproductive system

Ovary
The role of NO in regulating ovarian function was evident from the observation that NO synthesis increases with follicular development. Moreover, the role of hormones in regulating NO synthesis during follicular development and ovulation was also obvious, as increases in NO correlated with increases in oestrogen (Rosselli et al., 1994a ; Figure  2 ). Similar changes in circulating NO concentrations with follicular development were observed in women undergoing in-vitro fertilization and treated sequentially with gonadotrophin-releasing hormone (GnRH) and human menopausal gonadotrophin and human chorionic gonadotrophin (HCG), thereby implicating other hormones [HCG, luteinizing hormone (LH), follicle stimulating hormone (FSH) and progesterone] in the regulation of NO synthesis and folliculogenesis (Rosselli et al., 1994a) . Subsequently, Shukovski and Tsafriri (1994) demonstrated that administration of NOS inhibitors, intraperitoneally or via the ovarian bursae, inhibits ovulation in the rat, thus providing evidence that NO participates in the ovulatory processes. Although the above findings provided evidence that NO regulates ovarian function, it remained unclear whether these effects were due to NO generated in the vasculature and neurons within the ovary or were due directly to NO generated by various cells within the ovary. The role of non-vascular NO in mediating the ovulation process was evident from the observation that a reduction of blood flow to the same extent as after NO inhibition does not suppress the ovulation rate to the same extent as blocking NO synthesis in perfused rat ovary (Bonello et al., 1996) . An indirect role of NO in Figure 2 . (A) Increases in serum nitrite/nitrate (stable metabolites of NO; ×100 µmol/l), 17β-oestradiol (nmol/l) and progesterone (nmol/l) concentrations with the development of follicles during spontaneous menstrual cycle in normal subjects. Data are means ± SEM; n = 7 subjects. (* = P < 0.05 versus samples collected at early follicular development). (B) Linear regression analysis showing the correlation between increases in serum nitrite/nitrate concentrations during follicular development phase of spontaneous menstrual cycle with 17β-oestradiol. Data represent all the samples taken from seven subjects, during follicular development. Reprinted with the permission of Rosselli et al. (1994a) and Biochem. Biophys. Res. Commun. regulating ovarian function was also evident from the finding that interleukin (IL)-1β, which induces NO synthesis, is involved in the ovulatory process (Bonello et al., 1996) .
Recent findings have provided direct evidence for the role of NO generated locally by ovarian cells, as well as NO generated within the ovarian vasculature, in regulating ovulation: Van Voorhis et al. (1995) demonstrated that mature rat ovaries express iNOS and eNOS, but not nNOS. iNOS was localized in the granulosa cells of primary, secondary and small antral follicles in the ovary, whereas eNOS was present in the blood vessels of the ovary. Stimulation of the ovary with gonadotrophin increased expression of both eNOS and iNOS, suggesting that both isoforms participate in the ovulatory process; however, whether they play different roles could not be concluded from these studies.
Because of the lack of inhibitors to inhibit different isoforms of NOS specifically, it has been difficult to evaluate the roles of iNOS and eNOS in the ovulatory process. However, inhibition of iNOS using the specific inhibitor N g -methyl-L-arginine and the putatively specific inhibitor aminoguanidine has been shown to inhibit ovulation in rats, in a dose-dependent manner (Shukorski and Tsafriri, 1994) , suggesting that iNOS is involved in the ovulatory process. Since, inhibition of iNOS reduced ovulation by a maximum of 54%, it is feasible that eNOS also participates in this process. Immunohistochemical localization of eNOS and iNOS in various ovarian cells during follicular development demonstrated a distinct cell-specific expression pattern that was differentially regulated (Zackrisson et al., 1996; Jablonkashariff and Olson, 1997) . In control ovaries, eNOS was expressed in the theca cell layer, ovarian stroma and the surface of the oocytes. During follicular development, eNOS was expressed in theca cells and in mural granulosa cells. After ovulation, homogeneous eNOS staining was observed in cells of the corpus luteum. Quantitative estimates revealed that as compared to control ovaries, eNOS concentrations increased by 2.5-fold after pregnant mare's serum gonadotrophin induced follicle growth, and further by 5-7-fold in response to HCG administration. In the same study, the pattern and cell-specific expression of iNOS during follicular development was found to be different from that observed for eNOS. In immature ovaries and during follicular development, iNOS expression was found within the theca cell layer and stroma. After ovulation, iNOS was expressed in the external layers of corpus luteum, but in the degenerating corpus luteum, strong staining was observed in the non-parenchymal cells in the entire corpus luteum. Quantitative estimates of iNOS showed that, in contrast to eNOS, iNOS concentrations did not change during follicular development. However, a 6-and a 10-fold increase in iNOS was observed at the time of ovulatory HCG injection and 10 days after HCG injection respectively. The above findings provide evidence that intra-ovarian eNOS and iNOS regulate the ovulatory process simultaneously. Because theca cells, granulosaluteal cells and cells of the corpus luteum are involved in steroidogenesis, it is feasible that NO also regulates steroid synthesis (see the section on steroidogenesis).
In most organs, iNOS is only expressed in response to an immune stimulus such as infection or trauma. The physiological relevance of the expression of iNOS in normal ovaries at all stages is unclear. It is feasible that this expression is without any functional importance and largely due to the presence of macrophages and IL-1β in the ovary. Alternatively, since the follicles are continuously being generated and regulated by growth factors, it is feasible that iNOS-derived NO acts as a growth regulatory molecule. In this regard, it is interesting to note that NO has dual effects on cell growth. NO alone inhibits smooth muscle cell growth, however, in the presence of basic fibroblast growth factor (bFGF), NO is a potent mitogen and induces smooth muscle cell growth (Dubey et al., 1997) . Similarly, IL-1β-induced NO synthesis has been shown to enhance bFGF-induced growth of smooth muscle cells (Dubey et al., 1997) . Because IL-1β as well as bFGF are importantly involved in follicular growth (Adashi, 1989; Hurwitz et al., 1992; Kaipia and Hsueh, 1997) , it is feasible that NO facilitates this process. The growth-promoting effects of NO within the ovary are also evident from the findings that (i) NO donors increase, whereas NO synthesis inhibitors decrease, the receptors for epidermal growth factor (a potent growth factor) on granulosa cells (Hattori et al., 1996) ; (ii) NO mediates gonadotrophin-stimulated regulation of the blood-follicle barrier (Powers et al., 1995) ; (iii) NO mediates IL-1β-induced expression of glucose transporter 3 (Kol et al., 1997) . Because glucose increases during mid-cycle and glucose stimulates NO synthesis, it is feasible that NO and glucose facilitate follicle development in a complimentary fashion.
The importance of IL-1β-induced NOS and NO synthesis in regulating ovarian function was deduced from the observation that, in contrast to IL-1β, LPS and IFN-γ were unable to induce iNOS activity in cultured granulosa cells (Tabraue et al., 1997) . Moreover, IL-1β increased guanosine triphosphate cyclohydrolase (GTP-CH) activity, the rate-limiting step for de-novo biosynthesis of tetrahydrobiopterin (THB), which is an essential factor for iNOS activity. Similar to IL-1β, FSH induces GTP-CH activity and enhances the effects of IL-1β (Tabraue et al., 1997) . Although earlier studies with isolated ovarian dispersions suggested that IL-1β may play an important role in mediating toxic effects and cell death (Ellman et al., 1993) , subsequent studies provided evidence that IL-1β-induced cell toxicity was not NO mediated (Ben-Shlomo et al., 1994) . Moreover, NO seems also not to be an obligatory mediator of IL-1 effects on plasminogen activation and prostaglandin E generation in rat ovary (Huwitz et al., 1997) .
Folliculogenesis involves the participation of both growth and programmed cell death, and NO regulates both of these processes. It is feasible that the participation of NO in both these processes largely depends on interactions with other factors generated within the ovary. With regard to apoptosis, several lines of evidence suggest that NO prevents it. Sugino et al. (1996) studied the relationship between NO concentrations in follicular fluid and apoptosis. They demonstrated that, compared to large and medium-sized follicles, smaller follicles had a higher incidence of apoptosis, although NO (nitrite/nitrate), arginine and citrulline concentrations in these follicles did not differ. Similarly, DNA fragmentation studies revealed that IL-1β-induced anti-apoptotic effects in cultured follicles were NO-mediated (Chun et al., 1995) . Moreover, Anteby et al. (1996) noted that NO concentrations were increased in human follicular fluid, and these values were positively correlated with follicular volume and oestradiol concentrations. Together, these observation suggest that local generation of NO induces follicle development and not apoptosis. Although low concentrations of NO may prevent apoptosis, pathologically high concentrations of NO, as well as increased O 2 -generation by NOS due to lack of arginine, may promote cell death, via peroxynitrite generation.
In conclusion, the above findings provide convincing evidence that NO, both ovarian cell-derived and vascular endothelial cell-derived, plays an important role in the physiology and biology of the ovary with regard to regulation of folliculogenesis and ovulation. The clinical implications of these findings have not yet been addressed. Future studies are needed to investigate whether the ovarian dysfunction observed in certain pathological conditions is associated with decreased vascular and intra-ovarian NO synthesis and whether these defects can be corrected by NO. It may be possible to treat ovarian dysfunction related to decreased perfusion of the ovary in vaso-occlusive disorders either directly by administering NO donors or indirectly via administration of IL-1β.
Oviduct
In oviducts, enhancement of endothelin-induced contraction in the presence of L-NAME provided the first evidence for the presence as well as a physiological role of NO in regulating oviduct function (Rosselli et al., 1994b) . Ekerhovd et al. (1997) provided evidence that NO mediates contractile activity in isolated strips of human Fallopian tube. Subsequently, Bryant et al. (1995) as well as studies from our laboratory reported the presence of calcium-dependent as well as independent forms of NOS in rat, bovine and human oviducts ( Figure 3 ). Immunostaining revealed the presence of eNOS in the epithelial cells of the oviduct; moreover, IL-1β stimulated NO synthesis in both human and bovine oviducts. The distribution of calcium-dependent NOS activity was not different in the isthmus, fimbria and ampulla . However, NOS activity in the oviduct was relatively low during pro-oestrus, as compared to all other stages of the oestrus cycle. Since the oviduct plays a critical functional role by being the site of fertilization and early embryonic development, it is feasible that NO may play an important role in promoting this process. Basal release of NO may promote sperm motility and protect the ovum as well as the spermatozoa against oxygen free radical-induced damage. Because NO has been shown to regulate contractility of the Fallopian tube (Rosselli et al., 1994b) , it may also regulate ciliary beating of the ciliated epithelial cells. NO has been shown to up-regulate the receptors for growth factors such as epidermal growth factor as well as those for anchoring proteins and integrins (Hattori et al., 1996; Dubey et al., 1997) . It is feasible that, during early embryonic development, NO primes the embryo to develop these growth regulating and anchoring proteins on the cell surface and this eventually facilitates implantation within the uterus.
In contrast to the physiological situation, NO synthesis within the oviduct may increase under certain pathological conditions, such as infection or endometriosis, and this may evidently lead to decreased fertilization via deleterious/toxic effects on the spermatocytes as well as on the oocyte. Moreover, increased generation of NO may also influence ciliary beats and thus embryo transport, and may consequently result in abortion. With regard to the expression of NOS within the oviduct under pathological conditions, we compared the expression of eNOS and iNOS in oviducts obtained from normal cycling women, postpartum patients, patients with extrauterine pregnancies and postmenopausal women. eNOS was localized in the epithelium lining of all the oviducts from all the four groups. In contrast, iNOS expression was only observed in groups of cells present in the muscle layer of oviducts obtained from postpartum patients, whereas in oviducts obtained from patients with an extrauterine pregnancy (personal communication, Rosselli et al., 1997) iNOS expression was observed all through the muscle and epithelial layers. Together, these findings suggest that NO plays an important role in the physiology as well as the pathophysiology/pathobiology of the oviduct.
Uterus
The uterus undergoes important structural alterations in pregnancy as well as during menstruation. Because NO regulates smooth muscle cell contractility, and spontaneous contraction as well as distension of the uterus (B) Inducible NOS activity in bovine oviducts. Production of NO was measured by analysing the concentrations of nitrite/nitrate in the incubation medium in which ampullary segments were incubated for 36 h in: Hanks' balanced salt solution (control), 7.3 mM L-arginine, L-arginine + 10 µg/ml lipopolysaccharide (LPS), L-arginine + LPS + 1 mM L-NMMA (LPS + L-NMMA). Each bar represents the mean ± SEM from three experiments. Reprinted with the permission of Rosselli et al. (1996) and Mol. Hum. Reprod. during pregnancy, the role of NO in regulating the pathophysiology and biology of the uterus has gained intense attention. Uterine vasculature as well as nerve supply both express NOS activity and have been shown to modulate the contractile effects of multiple vasoactive factors (Azuma et al., 1995; Dong and Yallamplalli, 1996; Jaing et al., 1996; Magness et al., 1996 Magness et al., , 1997 Veille et al., 1996) . Apart from in the vessel wall and neurons, the presence of NOS has been demonstrated in glandular epithelium, endometrial stromal cells, myometrial smooth muscle cells and mast cells, suggesting that NO plays a local role in the control of uterine function (Telfer et al., Figure 4 . Nitrite production by the non-pregnant (NP) and pregnant rat uterus (A) and cervix (B) during gestation (days 19-21), day 22 morning of the delivery date (22NL), during term delivery (22L) and 1 day post-partum (pp1). Statistical analysis consisted of analysis of variance (ANO-VA) followed by post-hoc tests using Fisher's least significance criteria. Means (±SEM) with at least one common superscript were not different at a value of P < 0.05, n = 5 animals in each group. Reprinted with the permission of Buhimschi et al. (1996) and Hum. Reprod. 1995). Although myometrial smooth muscle cells express eNOS (Gangula et al., 1997) , it is one of the rare tissues which expresses iNOS even under unstimulated conditions (Buhimschi et al., 1996; Bansal et al., 1997) . The expression of eNOS and iNOS in non-pregnant and decidualized human endometrium was also comprehensively studied by Telfer et al. (1997) . The physiological role of eNOS and iNOS during pregnancy and labour was studied in depth by Buhimschi et al. (1996) , who demonstrated that both eNOS and iNOS are up-regulated during pregnancy but decreased when labour begins (Figure 4 ). Gestational differences in the response to NO are well established. It has been shown that, during pregnancy, the relaxing effects of NO are enhanced, compared with the uterus during term or preterm labour (Natuzzi et al., 1993; Sladek et al., 1993; Yallampalli et al., 1994; Buhimschi et al., 1995b Buhimschi et al., , 1996 . The above findings, together with the observations that (i) nitroglycerine relaxes the uterus to facilitate extraction of retained placenta (Peng et al., 1989) , (ii) nitroglycerine arrests preterm labour and prolongs gestation (Lees et al., 1994) , (iii) amyl nitrate decreases the magnitude of uterine contractions induced by oxytocin, but not spontaneous activity (Kumar et al., 1965) and (iv) NO donors inhibit uterine contractions in pregnant rhesus monkeys, sheep and rats as well as humans (Jennings et al., 1993; Yallampalli et al., 1993; Heymann et al., 1994; Buhimschi et al., 1995b) , provide compelling evidence that NO differentially controls uterine contractility during pregnancy and labour (Figure 4 ). Data with regard to the regulation of NO synthesis in pregnancy and labour suggest that iNOS, but not eNOS, is the key player in regulating contractile function. It has been shown that NOS activity increases in rat uterus during pregnancy and falls at term (Natuzzi et al., 1993) . Expression of rat myometrial iNOS has been shown to be up-regulated in pregnancy and fall at term (Riemer et al., 1997) . Similar up-regulation of NOS activity in the uterus during pregnancy has also been demonstrated in rabbits (Sladek et al., 1993) . Moreover, in a recent study, demonstrated that in humans expression of myometrial iNOS activity was highest in pre-term not-in-labour patients, fell by 75% at term and was barely detectable in pre-term in-labour or term in-labour patients. They also demonstrated that, compared to pregnant subjects, there was no positive staining for iNOS in myometrial myocytes in non-pregnant subjects ( Figure 5 ). Together, these findings provide convincing evidence that NO plays a key role during pregnancy and labour.
Which factors regulate iNOS activity in pregnancy are still unclear. In this regard, the role of cytokines is of most importance as they simultaneously increase during pregnancy (Das et al., 1992; Bry and Hallman, 1993) . Cytokines such as IL-1β and TNF-α are known to increase iNOS expression and induce NO synthesis, whereas cytokines such as IL-4, IL-10 and transforming growth factor (TGF)-β are known to inhibit iNOS activity (Davies et al., 1995) . It is feasible that the increases in NOS activity during pregnancy are due to positively regulating cytokines and the subsequent decrease during labour is Figure 5 . Percentage of myocytes containing inducible calcium-independent form of nitric oxide synthase (iNOS) within each group of myometrial biopsies during pregnancy (mean ± SEM). The number of patients within each group was as follows: preterm no labour, n = 5; preterm labour, n = 3; term labour, n = 9; term labour, n = 5. * = significantly greater than each of the other three groups (P < 0.0001). Reprinted with the permission of Bansal et al. (1997) and J. Clin. Invest.
largely due to inhibitory cytokines. An interrelationship between the cyclo-oxygenase pathway, nitric oxide and cytokines has also been demonstrated within the rat uterus and may importantly regulate uterine function in pregnancy . Ovarian hormones have also been shown to induce iNOS in the uterus and may regulate uterine function (Yallampalli et al., 1994; Huang et al., 1995) . Although the role of iNOS is evident, the role of eNOS in the endometrial epithelial and stromal cells is unclear. It is feasible that continuous generation of NO into the lumen facilitates processes such as menstruation and implantation via prostaglandin synthesis and modulation of anchoring proteins respectively. eNOS-derived NO may act as an alternative inhibitor of endometrial platelet aggregation via activation of soluble guanylyl cyclase generation or via cyclo-oxygenase catalysis. Moreover, local synthesis of NO within the uterus may be important for regulating myometrial activity, i.e. spontaneous contraction of the uterus. The role of NO in pregnancy has recently been reviewed by Sladek et al. (1997) . Buhimschi et al. (1996) demonstrated that rat cervix expresses all three isoforms of NOS, i.e. iNOS, nNOS and eNOS. Furthermore, they demonstrated that expression of iNOS is increased in the cervix, and decreased in the uterus, during parturition and preterm labour (Figure 4) . Moreover, nNOS, which was not expressed in the uterus during gestation, increased in the cervix during labour. In contrast to nNOS and iNOS, no significant changes were observed in eNOS expression during labour at term. These findings suggest that NOS activity in the uterus and cervix is differentially regulated during labour and may be involved in connective tissue remodelling during cervical ripening. The physiological and biological relevance of NO in pregnancy and labour comes from their finding that the inhibition of NO synthesis by administration of L-NAME prolonged the duration of delivery, the interval between each pup's expulsion (Figure 6 ), as well as decreasing cervical extensibility. These findings not only suggest the importance of NO synthesis in the uterus and cervix during labour and pregnancy, but also point to the role of various isoforms of NOS in regulating these effects. Which factors regulate the induction of iNOS may have important therapeutic implications, as administration of agents which selectively induce iNOS activity may induce cervical ripening and labour in patients with difficult labour. Indeed, cytokines as well as matrix factors are known to induce iNOS activity (Dubey et al., 1997) , whereas NO modulates connective tissue-degrading enzymes, i.e. matrix metalloproteases (Evans et al., 1995; Kolpakov et al., 1995) . Since these factors are increased during pregnancy and cervical ripening, they may be modulating iNOS activity, which in turn helps in labour. Changes in hormones and their receptors are known to occur during pregnancy and labour, and they could regulate cervical NOS activity. In a recent study, Ali et al. (1997) provide evidence that changes in uterine and cervical NOS activity are progesterone dependent. Further studies are needed to study the effects of various matrix factors, hormones and cytokines on cervical and uterine NOS activity.
Cervix and vagina
NOS activity has also been localized in the vagina. eNOS activity is localized in the stratified squamous epithelial lining and in smooth muscle cells (Chatterjee et al., 1996) . The expression of eNOS was maximal during oestrus and pro-oestrus, suggesting that NO may stimulate vaginal secretion. NOS immunoreactive axons and neurons have also been shown to be present in the vagina, moreover the most abundant NO-releasing innervation has been shown to be present in the cervix and vagina (Grozdanovic et al., 1994) .
Placenta and pre-eclampsia
The relationship between the placenta and NO has recently been reviewed by Buhimschi et al. (1997) and is discussed only briefly here. Although uterine cell-derived NO is important in pregnancy and labour, vascular NO seems to be important in pathological conditions such as preeclampsia. Moreover, the placental vasculature seems to be Figure 6 . (A) Duration of delivery (in minutes) in rats infused with N-nitro-L-arginine methyl ester (L-NAME; 50 mg/day) versus control animals. Means (±SEM) marked with an asterisk were significantly different from control at a value of P < 0.05 (unpaired t test). (B) The interval between each pup's expulsion (pup interval) in rats infused with L-NAME (50 mg/day) and controls. Means (±SEM) marked with an asterisk were significantly different from control at a value of P < 0.01 (unpaired t test); n= 18 in each group. Reprinted with the permission of Buhimschi et al. (1996) and Hum. Reprod. more important in the pathophysiology of pre-eclampsia. Both iNOS and eNOS are expressed within the placenta (Myatt et al., 1993) . Indirect evidence for the role of NO in pre-eclampsia comes from the studies of Buhimschi et al. (1995a) , who demonstrated that administration of L-NAME (competes with L-arginine and inhibits NO synthesis) to pregnant rats resulted in a pre-eclampsia-like condition. Moreover, administration of L-arginine to rats infused with L-NAME reversed both the increase in blood pressure and the decrease in fetal weights observed with L-NAME alone. Although these findings suggest that inhibition of NO causes pre-eclampsia-like conditions, they do not prove that NO deficiency causes preeclampsia. Indeed, a recent study by Yallampalli et al. (1996) demonstrated that calcitonin gene-related peptide reduces fetal mortality and reverses hypertension in a L-NAME-induced pre-eclampsia-like condition. Taken together, these findings suggest that vasoconstriction caused by decreased synthesis of NO within the vasculature can cause pre-eclampsia and that agents that induce vasodilatation via NO generation, or independent of NO generation, may be therapeutically important in preventing pre-eclampsia-associated disorders.
Although the above findings suggest a role of NO in pre-eclampsia, direct evidence for this association is still lacking. Myatt et al. (1997) recently demonstrated that expression of eNOS, and hence NO synthesis, is increased in the fetal-placental vasculature obtained from patients suffering from pre-eclampsia with or without intrauterine growth restriction. This implies that the increase in eNOS expression in the fetal-placental vasculature of preeclamptic subjects may be an adaptive response to the increased resistance, poor perfusion and hypoxia. Indeed, shear stress and hypoxia are known to induce eNOS activity (Kelly et al., 1996) . Moreover, an increase in NO synthesis as a compensatory mechanism to reduce blood pressure has shown to occur in rats with '1 Kidney 1 Clip'-induced hypertension, as well as in spontaneously hypertensive rats (Arnal et al., 1993; Dubey et al., 1996) . In a recent study, Myatt et al. (1996) demonstrated the presence of intense NOS staining and the presence of nitrotyrosine residues in the endothelial lining of placental villus of pre-eclamptic placenta. Moreover, they provided evidence for peroxynitrite formation and action in mediating endothelial damage (Myatt et al., 1996) In the light of the findings that L-NAME induces pre-eclampsia-like conditions in rats (Buhimschi et al., 1996) whereas increased eNOS activity was observed in the placental-fetal microcirculation in humans, how do we explain the role of NO synthesis in pre-eclampsia? Moreover, most emphasis has been focused on the vasodilatory effects of NO and very little is known about the effects of NO on the growth of smooth muscle cells in the placental-fetal microcirculation. Indeed, abnormal growth of smooth muscle cells contributes to the remodelling process associated with the vaso-occlusive disorders observed in the placental-fetal microvessels. Since NO has been shown to regulate smooth muscle cell growth differentially, i.e. inhibit as well as induce growth, the regulatory effects of NO on placental-fetal microvascular smooth muscle cells may be important in pre-eclampsia and need to be investigated. Alternatively, it is feasible that these differences in NO synthesis may be due to species differences.
Decreased NO synthesis within the vasculature may be a consequence of either damaged/dysfunctional endothelium, decreased substrate (L-arginine) availability, or an increased presence of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of NO synthesis known to increase in pre-eclampsia (Fickling et al., 1993) . It is plausible that L-arginine substitution may increase NO synthesis by improving endothelial function as well as by competing with endogenous NO inhibitors such as ADMA. Hence, future studies should aim to evaluate whether administration of L-arginine protects against the disorders associated with pre-eclampsia. Moreover, it needs to be demonstrated whether lack of NO synthesis alone or other vasodilators, such as adenosine, prostaglandins etc., also cause pre-eclampsia-like conditions. From the therapeutic point of view, agents which induce vasodilation or counteract vasoconstriction and prevent endothelial dysfunction may prove to be useful in treating patients with pre-eclampsia. In this regard, endothelin antagonists, adenosine agonists and vasodilatory hormones (oestrogen, progesterone) may also be beneficial and they need to be investigated. Finally, since most vasoconstrictors induce and vasodilators inhibit the growth of vascular smooth muscle cells, the role of NO in regulating mitogen/vasoconstrictor-induced growth of fetal-placental microvascular smooth muscle cells needs to be evaluated.
NO in the male reproductive system
Regulation of penile erection
In 1990, Ignarro et al. (1990) first demonstrated that electrical field stimulation of isolated strips of rabbit corpus cavernosum promotes the endogenous formation and release of NO. Based on this observation, they postulated that penile erection is mediated by NO generated in response to non-adrenergic-non-cholinergic neurotransmission. Subsequently, Holmquist et al. (1991) provided in-vivo evidence that the arginine/NO pathway induces penile erection in rabbits. Following this finding, the endogenous regulation of NO and the mechanisms by which it regulates penile erection have been a subject of intense research. NOS activity was localized in the rat penile neurons innervating the corpora cavernosa and to neuronal plexuses in the adventitial layer of penile arteries (Burnett et al., 1992) , suggesting that NO is a physiological mediator of erectile function. Apart from the nerves, eNOS is also abundantly present in the endothelium of penile vasculature and sinusoidal endothelium within the corpora cavernosa (Burnett et al., 1996) . Moreover, pineal cells have also been shown to express NOS activity (Maronde et al., 1995) .
Neuronal NOS seems to play a decisive role in mediating penile erection (Burnett et al., 1996) . In humans, NOS activity has been identified in discrete neuronal locations, including the pelvic plexus, cavernous nerves and their terminal endings within the corporeal erectile tissue, branches of the dorsal penile nerves and nerve plexuses in the adventitia of the deep cavernous arteries (Burnett et al., 1993) . NOS-containing innervation of the sympathetic preganglionic neurons from the spinal cord to the penis has also been shown recently (Vanhatalo and Soinila, 1995) . The above findings suggest that NO affects penile erection at several neuronal levels (Vanhatalo et al., 1996) . Additionally, direct injection of L-NAME into the paraventricular nucleus, but not into the caudate nucleus, medial septum, pre-optic area and the CA1 field of the hippocampus, inhibited apomorphine-and oxytocininduced penile erection. These findings suggest that actions of NO in the brain, and distal from the peripheral nerves, can also influence penile erection (Melis et al., 1994a) . Moreover, in mice lacking nNOS, eNOS has been shown to mediate NO-dependent penile erection (Burnett et al., 1996) . Together, these findings suggest that both nNOS and eNOS are capable of regulating penile erection. Because NO acts as a mediator of penile erection, factors regulating nNOS or eNOS may differentially induce penile erection.
Neuronal NOS from the rat penile corpora cavernosa has been cloned by Magee et al. (1996) . The penile cNOS differs from the cerebral nNOS by the presence of a 102 nucleotides stretch. The mRNA is expressed in the rat penis, urethra, prostate and skeletal muscle, coexists with the cerebellar nNOS in the pelvic plexus and bladder, and is detectable in the cerebellum. The features of penile nNOS suggest that it may be regulated differentially from the cerebellar nNOS. In addition to eNOS and nNOS, iNOS is expressed in the cavernosal smooth muscle cells of the penis . Both the rat and the human penile iNOS have recently been cloned and have several amino acid differences from their analogous isoform in nonpenile tissues . Because erectile dysfunction is associated with reduction in nNOS activity as well as reduction in penile smooth muscle cell compliance (Regazzi et al., 1996; Carrier et al., 1997) , the cloning of these NOS isoforms may open the way for their possible use in the management of erectile dysfunction. Indeed, induction of iNOS locally by injecting a mixture of iNOS inducers corrected the erectile dysfunction observed in old rats. Moreover, administration of rat penile iNOS cDNA mitigated the ageing-associated erectile dysfunction .
Several lines of evidence suggest that the NO-cGMP pathway is largely responsible for mediating the erectile response to administration of N-methyl-D-aspartic acid (Melis et al., 1994b) , acetylcholine (Champion et al., 1997) , oxytocin (Melis et al., 1994a) , apomorphine (Melis et al. 1994a) , cocaine (Chan et al., 1996) , androgens (Penson et al., 1996) , testosterone (Zvara et al., 1995) , dihydrotestosterone (Lugg et al., 1995) , electrical stimulation (Holmquist et al., 1991) and dopamine (Melis et al., 1996) . In contrast, vasoactive intestinal peptide-and adrenomedullin-induced penile erections were not reversed by L-NAME, a NO synthesis inhibitor, suggesting that NO-independent pathways also participate in penile erection (Hayashida et al., 1996; Champion et al., 1997) . Together, these findings reaffirm the importance and the possible use of NO donors as a therapeutic agent in correcting penile erection. Because the effects of NO are largely local within the penis, and NO is a labile substance with an ultrashort half-life, application of the pharmacologically active substances directly to the end organ may enable the achievement of time-dependent high local drug concentrations without severe systemic side effects. Indeed, linsidomine (SIN-1), a NO donor, has been successfully used to correct erection disorders in men (Stief et al., 1992) .
Regulation of penile erection by androgens and the pituitary and its relationship with NOS activity is of special physiological interest. Deficiency of androgens, such as testosterone, has long been associated with impotence and dysfunction of penile erection Penson et al., 1996) . Indeed, castration results in a significant decrease in eNOS and cNOS activity in the penis and reduces electrical stimulation-induced penile erection by 70% (Lugg et al., 1996; Penson et al., 1996) . Administration of the anti-androgen flutamide to intact rats similarly reduced eNOS and nNOS activity and penile erection. In castrated rats treated with flutamide, the erectile response was abolished completely; however, NOS activity was not decreased below the values observed in castrated rats. Oestradiol administration to castrated rats, hypophysectomy or GnRH antagonist treatment in intact rats diminished the erectile response, below the level in castrated animals. Moreover, in hypophysectomized rats, penile NOS activity fell below levels in castrated animals. These data suggest that penile erection in the rat is completely dependent on androgens, presumably because of their role in the maintenance of penile NOS activity and of other ancillary factors (Penson et al., 1996) .
Erectile dysfunction occurs in diseases such as diabetes I and II and is accompanied by hypogonadism, as well as a significant decrease in nNOS content and activity in the penis (Vernet et al., 1995; Rehman et al., 1997) . It is feasible that administration of androgens or NO donors to diabetic rats may be therapeutically important to improve NOS content/activity and improve penile erection. Oxygen tension is known to regulate NO synthesis, and a low pO 2 inhibits NOS activity in the corpus cavernosum cytosol (Kim et al., 1993) . In the same manner, smoking leads to considerable decreases in penile NOS activity and nNOS content that are not reflected in a reduction of the erectile response to electrical stimulation (Xia et al., 1997) . Lack of effect on penile erection could largely be due to compensatory synthesis of NO by other NOS isoforms. Indeed, eNOS activity in rats exposed to smoke was not influenced (Xia et al., 1997) , and eNOS has been shown to induce penile erection in nNOS-deficient mice (Burnett et al., 1996) . Erectile function is also decreased in old and senescent rats. As compared to young rats, soluble penile NOS activity as well as NOS-containing fibres decreased in old rats Carrier et al., 1997) . Moreover, although the erectile mechanism appears to remain intact as rats age, the response to central and peripheral stimulation decreases, and the reduction in NOS-containing fibres might account for these observations. In conclusion, NO plays a decisive role in regulating penile erection, and local application of NO donors as well as gene therapy may prove to be of clinical and therapeutic benefit in the treatment of penile erection disorders.
Testis
Presence of low levels of cNOS activity in the testes and high levels in other male urogenital organs (urethra, bladder neck, vas deferens, prostate, seminal vesicle) was first reported by Ehren et al. (1994) . This finding was subsequently confirmed by immunohistochemical localization (Burnett et al., 1995) . The important role of NO within the testis was also evident from the findings that the testis contains: (i) GTP-cyclohydrolase I, the initial enzyme for THB synthesis (Milstien et al., 1996) ; (ii) arginosuccinate synthetase as well as argininosuccinate lyase, the enzymes responsible for L-arginine generation, and they are abundant in the testis and (iii) haem oxygenase isozymes HO-1 and HO-2, which oxidatively cleave the haem molecule to produce NOS (Ewing and Maines, 1995) . In addition, in rats treated with lipopolysaccharide, NOS-synthase is co-induced with argininosuccinate synthetase and argininosuccinate lyase (Nagasaki et al., 1996) . To evaluate the physiological relevance for the presence of NOS activity, the distribution of NOS activity was subsequently characterized in various testicular cells. In this regard, cNOS activity was identified in the Leydig cells, Sertoli cells and endothelial cells of the human testis (Davidhoff et al., 1995; Zini et al., 1996) . Interestingly, soluble guanylate cyclase and cGMP were found to co-localize within the cytoplasm of the Leydig cells, some apically situated spermatids and residual bodies of seminiferous tubules (Davidhoff et al., 1997) . Testosterone, calmodulin, aspartate, glutamate and Ca 2+ /calmodulin-dependent protein kinase II have been shown to co-localize with NOS-I in Leydig cells (Davidoff et al., 1995) . Moreover, cytokine-induced NO synthesis and iNOS expression have also been demonstrated in cultured Sertoli cells (Stephan et al., 1995) as well as Leydig cells (Tatsumi et al., 1997) . These findings suggest that the testicular cells are well equipped with a NO-cGMP pathway, which may importantly participate in the regulation of testicular functions, such as spermatogenesis and steroidogenesis. Zini et al. (1996) demonstrated the expression of eNOS in both Sertoli and Leydig cells at all stages of spermatogenesis. eNOS activity was absent in normal germ cells but present in degenerating or apoptotic intra-epithelial germ cells. Additionally, intense eNOS expression was also observed in prematurely shed spermatocytes and spermatids, suggesting a role for eNOS in spermatogenesis and germ cell degeneration. Interestingly, eNOS activity is differentially expressed in Leydig cells, suggesting that concentrations of steroids in the cells may be regulating this activity and NO subsequently acts in an autocrine/paracrine fashion. Within the testis, NO has also been shown to regulate blood flow, cell permeability and contractile function of myofibroblasts, which in turn regulate steroid synthesis and transport (Adams et al., 1994; Davidhoff et al., 1995) . More recently, Wang et al. (1997) have identified a testis-specific variant of nNOS (TnNOS) in the testis. Because autocrine-paracrine factors are known to regulate steroidogenesis in the testis, the role of NO in regulating this process has been a subject of intense research and the findings are discussed in the steroidogenesis section of this review.
Sperm motility and fertilization
NO also regulates sperm motility, with low concentrations of NO enhancing (Hellstrom et al., 1994) and medium/high concentrations of NO decreasing sperm motility (Rosselli et al., 1995;  Figure 7A ). It is tempting to speculate that, under physiological conditions, small amounts of NO are generated and neutralize free radicals which inhibit sperm The correlation between nitrite/nitrate concentrations (nmol/10 6 spermatozoa) in seminal plasma and the percentage of immotile spermatozoa (r = 0.74, P < 0.01, Spearman rank coefficient = 0.677, P < 0.05). Reprinted with the permission of Rosselli et al. (1995) and Hum. Reprod. motility. Thereby low concentrations of NO may protect against O 2--mediated reduction of sperm motility. In contrast, excessive generation of NO under pathological conditions such as infection or endometriosis can cause sperm toxicity as well as reduce sperm motility by contributing to the formation of peroxynitrite, a highly toxic anion of peroxidation. Indeed, in semen collected from different subjects a positive correlation was observed between the concentrations of NO and the percentage of immotile spermatozoa (Rosselli et al., 1995;  Figure 7B) . Hence, the concentration of NO determines the effects on sperm motility and viability, and the concentration of NO in turn depends on the amount of NO generated, i.e. low (physiological conditions) and high (pathological conditions).
Although the above findings suggest a paracrine role of NO in regulating sperm motility, a recent study by Lewis et al. (1996) provides evidence for the presence of eNOS and bNOS in the human spermatozoon that regulates (increases) sperm motility in an autocrine fashion. Moreover, they demonstrated that, as compared to normozoospermic samples, the expression of eNOS and concentrations of NO generated were lower in asthenozoospermic samples, suggesting that decreased endogenous NO may influence sperm motility and hence fertilization. However, in contrast to these findings, Schaad et al. (1996) found no evidence for the presence of NOS activity in human spermatozoa. It is possible that these differences are due to the differences in procedures used to assay NO synthesis, and further studies will be required to confirm whether the spermatozoa contain NOS and whether endogenous sperm-derived NO regulates sperm motility. Schaad et al. (1996) also reported that human seminal plasma inhibits brain NOS activity and characterized it to be a heat-stable non-competitive inhibitor of bNOS. The physiological relevance of the presence of such an endogenous NO inhibitor is unclear. It is possible that ejaculation of spermatozoa into the female reproductive tract triggers an immune reaction, similar to that observed during bacterial infection or organ transplantation. This would induce iNOS activity and consequently result in the generation of large amounts of NO that can induce sperm toxicity, as reported by Rosselli et al. (1995) . Hence, presence of endogenous NO inhibitor in the seminal plasma could play a physiological role in inhibiting NOS activity (iNOS) and maintaining NO at low concentrations to prevent toxic damage to the spermatozoa and surrounding cells or to prevent the hypermotility of sperm associated with capacitation process. Moreover, presence of endogenous NO inhibitor may also prevent generation of ONOO -by inhibiting the generation of NO that would otherwise react with O 2-to form ONOO -.
Mechanisms by which NO can directly influence sperm motility may involve inhibition of mitochondrial respiration, as NO disrupts electron transfer in the respiratory chain (Szabo et al., 1996) . Apart from NO, L-arginine, the substrate for NOS, has also been shown to influence sperm viability. In men with abnormal spermatozoa the arginine content is lower than in normal men. Moreover, concentrations of arginase, the enzyme that catabolizes arginine, have been shown to increase in the seminal plasma (Papp et al., 1979) and treatment with L-arginine improves sperm motility (Jungling and Bunge, 1976) because physiological concentrations of L-arginine are needed to generate NO, whereas in the presence of low arginine, NOS generates O 2 -and ONOO - (Xia et al., 1996) . It is feasible that O 2 -and ONOO -eventually cause sperm toxicity/dysfunction in patients with low L-arginine (Tomlinson et al., 1992) . However, this possibility needs to be investigated further. Moreover, NO has been shown to stimulate prostaglandin E 2 (PGE 2 ), and 5-hydroxyeicosatetraenoic acid in mouse spermatozoa (Herrero et al., 1995) ; however, the significance of this finding remains unclear.
Steroidogenesis
The observations that (i) luteinizing hormone-releasing hormone (LHRH) is generated in the pre-optic area of the hypophysis, (ii) neurotransmitters regulate the synthesis of LHRH, (iii) the hypophysis is well endowed with neurons and nerve supply, and (iv) NO acts as a neurotransmitter and NOS is present in the brain as well as neurons, lead to the possible conclusion that NO regulates LHRH synthesis. Direct evidence supporting the notion that NO regulates LHRH synthesis comes from the in-vitro studies of Rettori et al. (1994) , who demonstrated that treatment of arcuate nucleus-median eminence explants (ANME) with sodium nitroprusside, a NO donor, increased LHRH release into the medium in a concentration-dependent manner. Moreover, the NO synthesis inhibitor L-NMMA inhibited norepinephrine-induced, but not basal release of LHRH. Following this observation, the mechanisms by which NO induces LHRH release have been explored in detail and the multiple pathways involved are shown in Figure 8 . In 1979, Ojeda et al. demonstrated that PGE 2 stimulates LHRH release both in vitro and in vivo. Subsequently, using radioimmunoassays as well as [ 14 C]arachidonate, Rettori et al. (1992) provided evidence that NO induces the release as well as the synthesis of PGE 2 from the hypothalamus. These findings also suggested that NO must activate the enzymes, i.e. cyclo-oxygenase which converts arachidonate to prostanoids. Subsequently, it was shown that NO activates both cyclo-oxygenase I and II (Salvemini, 1997) . Together, these findings provided evidence that NO induces LHRH release by increasing PGE 2 synthesis.
Similar to NO, norepinephrine induces LHRH release both in vivo and in vitro via α 1 -adrenergic receptors (Ojeda et al., 1979 (Ojeda et al., , 1986 Negro-Vilar et al., 1986) . Norepinephrine-induced LHRH synthesis is accompanied by an increase in PGE 2 concentration, and NOS synthesis inhibitors (L-NAME) as well as NO scavengers block the effects of norepinephrine on LHRH synthesis (Rettori et al., 1992; McCann and Rettori, 1996a) . These findings provide evidence that norepinephrine-induced LHRH synthesis is also mediated via NO-induced PGE 2 generation. Similar to norepinephrine, excitatory amino acids such as glutamic acid also induce LHRH release from the hypothalamus (Brann and Mahesh, 1994) . Because glutamic acid induces norepinephrine release in the brain, LHRH also stimulates the gonads via gonadotrophin release and this regulates the synthesis of sex steroids. PV, Portal vein; SNP, sodium nitroprusside; SNAP, S-nitroso-N-acetylpenicillamine; Ca i , calcium channel; NOS, nitric oxide synthase; sGC, soluble guanylyl cyclase; cGMP, cyclic GMP (cGMP); PLA 2 , phospholipase A 2 ; AA, arachidonic acid; Cyclox, cyclooxygenase; PGE 2 , prostaglandin E 2 ; NMDAn, NMDA nerve; NOn, NOergenic neuron; EAAn, EAA nerve; On, oxytocin nerve; LHRHn, LHRH nerve, GABAn, GABA nerve; NE-T, norepinephrine nerve terminal; ↑ increase; X, blockade; and ----, inhibitor. Modified with permission from McCann and Rettori (1996b) and Soc. Exp. Biol. Med. it was postulated that the effects of glutamic acid were mediated via norepinephrine-induced NO generation (Navarro et al., 1994) . In this regard, it has been shown that glutamic acid-induced LHRH release is inhibited by L-NMMA as well as by haemoglobin, a NO scavenger . Moreover, phentolamine blocked glutamic acid-, but not sodium nitroprusside-induced release of LHRH (Kamat et al., 1995) . The above findings, together with the observation that NO synthesis inhibitors abrogated, whereas NO-donors enhanced, N-methyl-D-aspartate (NMDA; stimulates NO release via NMDA receptors on NOergic neurons)-induced LHRH synthesis, suggests that NO derived from NO generating neurons induces LHRH release (Bonavera et al., 1993; Figure 8) . In addition to regulating norepinephrine-and excitatory amino acid-induced LHRH release, NO has also been shown to mediate KCl-induced LHRH release (Bonavera et al., 1993; Figure 8) .
Release of oxytocin in the hypothalamus by oxytocin neuronal endings is known to induce mating behaviour. Because progesterone is known to induce mating in ovariectomized, oestrogen-primed rats by sequentially stimulating the release of NO and LHRH, Rettori et al. (1997) recently postulated that oxytocin may also induce mating behaviour via NO-induced LHRH release. Using medial basal hypothalamic explants, they demonstrated that oxytocin stimulated LHRH, PGE 2 as well as NO release in the absence, but not in the presence, of L-NMMA. Moreover, they demonstrated that oxytocininduced NO release was inhibited by prazocine, an α 1 receptor blocker, thus providing evidence that oxytocin activates NOS by stimulating the release of norepinephrine (Figure 8 ). Another interesting observation made by this group was that incubation of neuronal lobe explants with sodium nitroprusside inhibited oxytocin release, thus suggesting that NO generated by oxytocin induces LHRH as well as inhibits oxytocin release by a negative feedback loop (Figure 8 ).
The release of LHRH is not continuous but pulsatile. Mechanisms regulating the pulsatile release of LHRH are still unclear; however, recent studies suggest that γ-aminobutyric acid (GABA) may importantly regulate this phenomenon. In contrast to the other neuroactive factors, GABA can both induce and inhibit LHRH release from the hypothalamus (McCann and Rettori, 1996a) . Via LHRH neurons in the medial pre-optic area GABA inhibits LHRH release, whereas via the neurons in the arcuate nucleus-median eminence region it stimulates LHRH release. In this regard, it has been shown that L-NMMA and haemoglobin prevent the inhibitory effects of GABA on LHRH release, suggesting that the inhibitory effects of GABA are NO mediated (Seilicovich et al., 1995; McCann and Rettori, 1996a; Figure 8) . Interestingly, the NO donor sodium nitroprusside stimulated the release of GABA from nucleus-median eminence explants, and these effects were largely blocked by the NO scavenger haemoglobin (McCann and Rettori, 1996a) . NO has also been shown to mediate potassium-induced GABA synthesis in this tissue. Together, these findings suggests NO is an important regulator of GABA synthesis (Figure 8) , and may be important in regulating the pulsatile release of LHRH. It is feasible that pulsatile release of norepinephrine from the noradrenergic terminals induces NO release which simultaneously increases both LHRH and GABA synthesis. Once the concentrations of GABA reach a threshold value it inhibits LHRH release, leading to a pulsatile profile; however, other mechanisms may also participate (for review, see McCann and Rettori, 1996b) .
The physiological importance of this regulation is that LHRH stimulates the pituitary and causes release of gonadotrophins, which in turn activates the gonads to produce sex steroids. In females, LHRH induces ovulation, whereas in males it induces spermatogenesis (McCann, 1982) . Moreover, LHRH not only regulates gonadal function but also secretion of steroids by both males and females (for review, see McCann, 1982; Jennes and Conn, 1994) . In-vivo studies with castrated male rats have shown that infusion of L-NMMA caused a cessation of LH but not FSH pulses, suggesting that NO was required for pulsatile LHRH release but not for the putative FSH releasing factor, which possibly controls the release of FSH (Rettori et al., 1993 . The physiological role of NO in mediating the steroid-induced LH surge has been determined by Aguan et al. (1996) , who demonstrated that administration of eNOS and bNOS, but not iNOS, antisense oligonucleotides into the third ventricle of ovariectomized rats attenuated the oestrogen+progesterone-induced surge in LH.
The pituitary is known to control the release of prolactin, a hormone required in reproduction and lactation. Interestingly, NOS has been localized in anterior pituitary cells, i.e. folliculostellate cells and gonadotropes (Ceccatelli et al., 1993) . Similar to LH, abrupt increases in the rate of prolactin release occur during the afternoon of pro-oestrus. It is feasible that NO or NO-induced pulsatile release of LHRH regulates the release of prolactin. Incubation of isolated hemipituitaries with the NO donor sodium nitroprusside suppressed prolactin release and this suppression was completely blocked by the NO scavenger haemoglobin. Incubation with NOS-synthesis inhibitors (L-NMMA) increased prolactin release, whereas treatment with cGMP inhibited it . These findings suggest that NO, via the cGMP pathway, inhibits prolactin release from the pituitary. Interestingly, dopamine, which is known to inhibit prolactin release, was ineffective in the presence of L-NMMA and haemoglobin, suggesting that its inhibitory effects were also mediated via NO. As compared to prolactin, NO did not alter basal release of LH, but blocked LHRH-induced LH release (Cecccatelli et al., 1993) . In contrast to these findings, Bonavera et al. (1994) have shown that oestradiol benzoate as well as oestradiol benzoate plus progesterone induced prolactin and LH, but not corticosterone surge in ovariectomized rats was significantly blocked by co-administration of L-NMMA, suggesting that NO induces both LH and prolactin release. It is feasible that differences between the two studies are due to the in-vitro and in-vivo systems used. Indeed, increases in prolactin in the in-vivo system may have been mediated via NO-induced release of factors known to regulate prolactin release.
NO has also been shown to regulate granulosa-luteal cell steroidogenesis (Van Voorhis et al., 1994) . NOS has been localized in the granulosa cell layer of follicles, theca cells, ovarian stroma, surface of oocytes, endothelium and adventitia of ovarian blood vessels. In cultured granulosa-luteal cells, treatment with S-nitroso-N-acetylpenicillamine (SNAP, a NO donor), but not cGMP, decreased the basal synthesis of both oestrogen and progesterone. Incubation of the same cells with L-NAME resulted in a significant increase in oestrogen and progesterone concentrations. These findings suggest that NO mediates its inhibitory effects via a cGMP-independent pathway. Indeed, SNAP inhibited the activity of aromatase, one of the enzymes responsible for steroid synthesis.
NOS activity has been demonstrated in both the Leydig and Sertoli cells of the testis (Davidoff et al., 1997) . Because these cells importantly regulate testosterone synthesis, it is feasible that NO also regulates testosterone synthesis. Most studies to date have provided evidence that NO is a negative regulator of testosterone synthesis (Adams et al., 1992; Welch et al., 1995) . In rats, alcohol-induced suppression of testosterone synthesis was reversed in the presence of L-NAME, suggesting that ethanol induces its effects via NO generation (Adams et al. 1993) . Administration, of L-NAME to male rats also increased testosterone concentrations, suggesting that NO down-regulates testosterone synthesis. In a recent study, Adams et al. (1996) showed that L-NAME abrogated morphine-induced suppression and HCG-induced release of testosterone synthesis, without altering LH secretion. Furthermore, L-NAME attenuated morphine's suppression of HCG-stimulated testosterone secretion, indicating that the effects occur directly in the testis and are not dependent on LH secretion. Because NO donors and L-NAME did not enhance the effects of morphine and the opioid antagonist naltrexone respectively, it is possible that the NO and opioids suppressed testosterone release via separate mechanisms. With regard to the mechanism by which NO suppresses testosterone release, Welch et al. (1995) have recently shown that HCG-induced testosterone synthesis in cultured Leydig cells was increased by L-NMMA and L-NAME, and accompanied by a decrease in intracellular cGMP. This finding suggests that NO mediates its effects via the cGMP pathway. Interestingly, Adams et al. (1994) also showed that in-vivo administration of vasodilators that do not generate NO, i.e. hydralazine and nicardipine, inhibited the basal release of testosterone as well as L-NAME-induced testosterone release. Together, these findings suggest that inhibitory effects of NO may also be regulated by changes in the perfusion within the vasculature; however, further studies are required to investigate this possibility.
Sexual behaviour
Ample evidence suggests that LHRH not only triggers the synthesis of gonadotrophins and gonadal steroids but also participates in regulating mating behaviour in vertebrates (Moss and MaCann, 1973; McCann, 1982; Sakuma and Pfaff, 1983; Figure 8) . In ovariectomized rats given oestrogen, injection of progesterone induced mating within 30 min, and this effect was blocked by antisera directed against LHRH (Sakuma and Pfaff, 1983) . Progesterone-as well oestrogen+progesterone-induced mating behaviour (judged by lordosis) was also blocked by L-NMMA and L-NAME, but not by D-NMMA (inactive in inhibiting NOS; Mani et al., 1994) . In contrast to NO synthesis inhibitors, administration of NO donors significantly induced lordosis and these effects were blocked by antisera against LHRH, suggesting that the NO-induced mating was LHRH mediated (Mani et al., 1994) . Recently, it was shown that oxytocin, which induces mating behaviour in both males and females, induced LHRH release via NO generation, suggesting that the sexual effects of oxytocin are NO mediated (Rettori et al., 1997) . NOS activity was also recently identified in the lordosis-relevant neurons of the ventromedial hypothalamus of female rats (Rachman et al., 1996) . NO also regulates mating behaviour in males, where NO via neuronal regulation mediates penile erection. Inhibition of NO synthesis has been shown to impair copulation and decrease the number of ex-copula erections, increase the number of seminal emissions, and decrease the latency to the first seminal emission, possibly by decreasing sympathetic nervous system activity (Hull et al., 1994) . In contrast to the above studies, excess and inappropriate sexual behaviour was observed in mice lacking nNOS (Nelson et al., 1995) . Together, these findings provide evidence that NO importantly regulates sexual as well as mating behaviour. This may have important clinical implications for patients with depressed mating behaviour, as therapeutic means of inducing NOS activity may correct these abnormalities.
Finally, NO synthesis may in part be controlled by the reproductive system and may contribute to sexual dimorphism. Oestradiol induces NOS mRNA expression in different tissues , and circulating concentrations of NO 2 /NO 3 directly correlate with oestradiol concentrations in ovulating patients (Rosselli et al., 1994a) . Clinical studies demonstrate that ovarian dysfunction is associated with cardiovascular disease and decreased endothelium-derived NO synthesis, whereas oestrogen substitution has cardioprotective effects and circulating concentrations of NO 2 /NO 3 are increased in postmenopausal women treated with oestrogen (Rosselli et al., 1995; Imthurn et al., 1997) . Elucidation of the precise role of NO in reproductive biology may provide an important link between the reproductive system and other systems in which NO is involved, such as the cardiovascular system. In summary, the fact that NO is involved in the physiology, biology and pathophysiology of the reproductive system may have great clinical implications in developing therapeutic strategies to prevent NO-related reproductive disorders. In this regard, use of NO donors such as L-arginine (substrate for NO synthesis), as well as NO synthesis inhibitors (L-NAME etc.) may prove to be therapeutically important in correcting impotence due to dysfunction in penile erection, infertility due to infection, labour, pre-eclampsia, abortion, extrauterine pregnancy, etc. Future studies should aim to evaluate the use of NO synthesis modulators for treating specific reproductive disorders.
